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Background: Multiple myeloma is a plasma cell neoplasm with acquired genetic abnormali-
ties  of clinical and prognostic importance. Multiple myeloma differs from other hematologic
malignancies due to a high fraction of low proliferating malignant plasma cells and the
paucity of plasma cells in bone marrow aspiration samples, making cytogenetic analysis
a  challenge. An abnormal karyotype is found in only one-third of patients with multiple
myeloma  and interphase ﬂuorescence in situ hybridization is the most useful test for study-
ing  the chromosomal abnormalities present in almost 90% of cases. However, it is necessary
to  study the genetic abnormalities in plasma cells after their identiﬁcation or selection by
morphology, immunophenotyping or sorting. Other challenges are the selection of the most
informative FISH panel and determining cut-off levels for FISH probes. This study reports
the  validation of interphase ﬂuorescence in situ hybridization using CD138 positive cells,
according to proposed guidelines published by the European Myeloma Network (EMN) in
2012.
Method: Bone marrow samples from patients with multiple myeloma were used to stan-
dardize a panel of ﬁve probes [1q ampliﬁcation, 13q14 deletion, 17p deletion, t(4;14), and
t(14;16)] in CD138+ cells puriﬁed by magnetic cell sorting.
Results: This test was validated with a low turnaround time and good reproducibility. Five of
six  samples showed genetic abnormalities. Monosomy/deletion 13 plus t(4;14) were found
in  two cases.
Conclusion: This technique together with magnetic cell sorting is effective and can be used
in  the routine laboratory practice. In addition, magnetic cell sorting provides a pure plasma
cell population that allows other molecular and genomic studies.©  2016 Associac¸a˜o Bra
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Introduction
Multiple myeloma (MM)  is a disease characterized by clonal
proliferation of plasma cells (PCs) in bone marrow, which
leads to bone marrow failure, skeletal lesions, suppression of
normal immunoglobulin synthesis and production of a mono-
clonal protein.1 This disease accounts for between 10% and
15% of hematological cancers. The median age at diagnosis is
60 years, and the evolution is heterogeneous, with the survival
time varying from a few months to more  than a decade.2,3
MM shows acquired genetic abnormalities of clinical
importance. In about half of the cases, the initial genetic
process involves a reciprocal translocation between the
immunoglobulin heavy (IgH) gene (14q32) and many  target
genes including CCND1 (11q13), FGFR3/MMSET (4p16) and MAF
(16q23).4,5
The study of cytogenetic abnormalities by karyotyping is
limited because of the low mitotic index of the malignant
PCs.6–8 Only 20–50% of the cases show clonal abnormal-
ities by G banding karyotype. However, the presence of
hypodiploidy or monosomy of chromosome 13 predicts poor
survival.9–13
Molecular studies show that most MM cases present
genetic abnormalities with interphase ﬂuorescence in situ
hybridization (iFISH) being the most useful cytogenetic tool
for their investigation.7,14,15 However, iFISH testing requires
previous identiﬁcation or selection of PCs by morphology,
immunophenotyping or sorting. Cell selection using the anti-
CD138 antibody can be performed using magnetic columns
or sorting. The major limitation of this approach is the con-
siderable loss of cells during the puriﬁcation process. In
the cytoplasmic immunoglobulin (Clg) ﬂuorescence in situ
hybridization (FISH) technique, PC detection is carried out
using ﬂuorescent anti-Kappa or anti-Lambda antibodies in
the PC cytoplasm and analysis is performed only using this
population.4,5,16
The other challenges in MM testing with FISH are probe
selection, the determination of cut-off levels and number
Anti-CD138 + Anti-dextran
Antibody complex
Magnetic beads
with dextran
Sample Add lysis solution Add cocktail Add magne
Figure 1 – Magnetic cell sorting (MACS) of CD138+ cells using the
Cocktail (Stemcell TechnologiesTM). 2 0 1 6;3  8(2):113–120
of PCs to be scored. The European Myeloma Network (EMN)
has organized two workshops on iFISH in MM.  In 2012, they
published some technical recommendations herein tran-
scribed from the paper:
(1) Material should be part of the ﬁrst draw of the aspirate;
(2) Samples should be sent at suitable times to allow for the
lengthy processing procedure;
(3) Most importantly, PCs must be puriﬁed or speciﬁcally
identiﬁed;
(4) Cut-off levels should be relatively conservative: 10% for
fusion or breakapart probes, and 20% for numerical
abnormalities;
(5) Informative probes should be combined for best effect;
(6) In specialist laboratories, a single experienced analyst is
considered adequate;
(7) At least 100 PCs should be scored;
(8) Essential abnormalities to test for are t(4;14), t(14;16) and
17p13 deletions;
(9) Suitable commercial probes should be available for clini-
cally relevant abnormalities;
(10) The clinical report should be expressed clearly and must
state the percentage of PC involved and the method used
for identiﬁcation”.4
Objective
This study aimed to standardize an iFISH panel test for MM for
its incorporation in laboratories as a routine cytogenetic test.
Methods
This research was evaluated by the Ethics Committee of the
Hospital (SGPP number 169913 – “Validation of laboratory tests
for Clinical Pathology Laboratory”). The study was conducted
in accordance with the Helsinki Declaration as revised in 2008.
Magnetic column
tic beads Insert tube in
magnetic column
Wash
 kit EasySepTM Human WB and BM CD138 Positive Selection
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supernatantFigure 2 – Flow cytometry 
Twelve bone marrow samples from patients diagnosed
ith MM received at the Cytogenetic Laboratory of a pri-
ate Hospital in Sao Paulo from March to October 2014
ere selected for this validation. The process is described in
igures 1–5.
agnetic  cell  sorting  of  CD138+ cells
his ﬁrst step was performed using the “EasySepTM Human
B”, “BM CD138 Positive Selection Cocktail” and “EasySepTM
hole Blood Magnetic Particles” (Stemcell TechnologiesTM) kits.
The process started less than 12 h after the sample was
ollected, at room temperature following the manufacturers’
rotocol. At the end of the process, the tube was removed
rom the magnetic column and the selected material was re-
uspended in 200 L of washed solution, which was used after
his step for ﬂow cytometry analysis and the harvest proce-
ure (Figure 1).
low  cytometry  analysis  of  magnetic  cell  sorting
nrichment
t least 100 cells (counted in a Neubauer chamber) of the mag-
etic cell sorting (MACS) enrichment sample were evaluated
Incubation at 37ºC
Figure 3 – Harvest procedure (hypotonic and ﬁxative
treatments).
116  rev bras hematol hemoter. 2 0 1 6;3  8(2):113–120
FISH
(Fluorescent in situ
hybridization)
One drop of fixed cells in slide
Add probes labeled
with fluorochromes
Target DNA
Probe and target DNAs are
denatured using a high
temperature incubation
Probes anneals to
target DNA Nucleus is stained
blue with DAPI
Figure 4 – FISH 
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probe hybridization was performed with a 100× objective ﬂu-Figure 5 – Probes panel (Cytocell Aquarius®).
by ﬂow cytometry. Anti-CD138-FTIC (B-A38 clone, Exbio), anti-
CD38-PE (T16 clone, Immunotech) and anti-CD45-PE-Cy5 (J33
clone, Immunotech) monoclonal antibodies (MoAb) were used
to identify bone marrow PCs. Flow analysis was carried out in
FACS CantoII equipment (Becton, Dickinson and Company).
Data analysis was performed using the BD FACS Diva soft-
ware  (Becton, Dickinson and Company, version 6.1.3, USA)
(Figure 2).
Harvest  procedure
Three milliliters of hypotonic potassium chloride solution (KCl
– 0.075 mol/L) were added to the MACS  enrichment sample
and incubated for 16 min  at 37 ◦C. After this time, 1 mL  of ﬁxa-
tive solution (Carnoy’s solution: 3:1 methanol/acetic acid) wasprocedure.
added and the tube was centrifuged at 1500 rpm for 8 min.
The supernatant was discarded; material was re-suspended in
3 mL  of Carnoy’s solution and centrifuged again at 1500 rpm for
8 min. The latter procedure was repeated two more  times and
the resulting pellet was used in the iFISH procedure (Figure 3).
Interphase  ﬂuorescence  in  situ  hybridization  procedure
The pellet obtained in the last step was re-suspended in
600–1000 L of Carnoy’s solution and centrifuged in a Cytospin
centrifuge at 1000 rpm for 5 min  (100–200 L of the mate-
rial for each slide). According to the manufactures’ protocol,
slides were pretreated in the following solutions: 2× SSC, 70%
ethanol, 85% ethanol and 100% ethanol for 2 min  at room
temperature. Ten microliters of Cytocell Aquarius® probe was
applied on a slide and coverslipped. This was done with each
different probe. Co-denaturation of the probe and target DNA
was performed on a hot plate at 75 ◦C for 5 min. Slides were
incubated for 12–16 h in a humid chamber for hybridization
and then were washed in 0.4× SSC solution at 42 ◦C for 2 min
followed by a second wash (2×  SSC + 0.1% NP40) at room tem-
perature for 1 min. Nuclei were counterstained with 10 L of
DAPI II (Cytocell Aquarius®) and coverslipped. Slides were
stored at 4 ◦C for 10 min  (Figure 4).
Probe  panel  selection  and  scoring
Five probes (Cytocell Aquarius®) were selected: Ampliﬁcation
1q dual color; Deletion 13q (RB1) dual color; Deletion 17p13.1
(P53) dual color; t(4;14) IGH/FGFR3 dual color, dual fusion and
t(14;16) IGH/MAF dual color, dual fusion. iFISH analysis oforescence microscope (Zeiss, Germany) with single and triple
emission ﬁlters. Images were captured using Isis software
(Zeiss, version 5.4.9, Germany). All slides were evaluated by
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phorbol 12-myristate 13-acetate) and cytokines (interleukin 6Figure 6 – Study design.
wo technicians (50 interphase nuclei each), totaling 100 cells.
n case of discrepant results, the analysis of another 50 cells
as carried out by a third technician (Figure 5).
etermination  of  the  cut-off  points
he EMN  cut-off level recommendation was followed: 10% for
usion and breakapart probes and 20% for numerical aberra-
ions.
esults
f the twelve bone marrow samples used in this validation
est, four were collected in EDTA and eight in heparin sodium.
one marrow samples collected in EDTA resulted in low purity
fter CD138+ selection and two samples in heparin sodium
xed in ethanol resulted in bad hybridization. Therefore, good
esults were obtained for only six samples collected in hep-
rin sodium treated with hypotonic solution (KCl) and ﬁxed in
arnoy’s solution. These results are shown in Figure 6.
The number of PCs detected by morphology on bone mar-
ow aspirate slides (not the impure specimen) ranged from
Table 1 – Interphase ﬂuorescence in situ hybridization and kary
Sample % of plasma cells in
bone marrow
aspirate (%)
%  CD138+ cells after
selection (%)
7 40.8 72.6 46,XX
8 22.0 70.4 46,XX
9 Not done 90.9 46,XX
10 17.6 89.6 46,XY
11 4.80 70 44,X,
Y,add
t(8;11
18,
+der(
+2ma
12 1.20 70 46,XX 1 6;3  8(2):113–120 117
1.2% to 82.8%. The median time from the sample arriving in
the laboratory to the start of the process was 3 h (range: 2–5 h).
After CD138+ selection, the sample purity ranged from 70 to
91%. A third analysis was performed for 40% of the probes,
mainly to conﬁrm atypical signals seen for the IgH probe.
Karyotype and iFISH results, described according to the
standards of the International System for Human Cytogenetic
Nomenclature (ISCN) 2013,17 are listed in Table 1.
Five of the six cases analyzed showed abnormal ﬁndings in
iFISH (Figure 7). Only one case (Sample 11) had abnormalities
found by both karyotyping (Figure 8) and iFISH. Both t(4;14)
and monosomy 13 were detected in two cases. Extra copies of
genes and abnormalities on chromosome 1 were also identi-
ﬁed.
Discussion
A number of different genomic abnormalities are associated
with MM.  However, their detection by karyotyping and FISH
can be limited due to the low proliferative rate of the PCs and
the percentage of clonal cells in the specimen, respectively.
Abnormal karyotypes are found in 20–50% of patients with
MM;  this rate can be even lower when MM is analyzed at
diagnosis.6,7 Karyotypes can show numerical and structural
aberrations with the most frequent numerical abnormal-
ities described being hyperdiploidy in 61–68% of patients,
pseudodiploidy in 9–20% and hypodiploidy, monosomy 13
and trisomy or tetrasomy of chromosome 9 in 10–30%.
Concerning non-random structural aberrations, 14q32
translocations and aberrations of chromosome 1 are found in
30% and 40–50% of cases with abnormal karyotypes, respec-
tively. The results of cytogenetic studies can be improved
using longer culture periods (72 h) and adding stimulating
agents such as 12-O-tetradecanoylphorbol-13-acetate (TPA orand granulocyte-macrophage colony-stimulating factor).7
The selection of PCs for iFISH analysis improved the detec-
tion of genetic aberrations in MM. Different methods are
otype results from six samples.
Karyotype FISH
20 Trisomy (total or partial) of
chromosomes 1, 4, 11, 13, 17
20 del(1p), del(16q) (MAF)
20 Monosomy 13, t(4;14)
20 1q ampliﬁcation,
monosomy 13, t(4;14)
-
(1)(p34),add(5)(q11.2),del(6)(q23),-7,
)(q24;q13),-12,add(13)(p11.2),-14,-16,-
19)t(1;19)(q23;p13)x2,add(20)(p13),
r[2]/46,XY[18]
Extra  copies of CDKN2C,
CKS1B,  P53 and FGFR3
20 Normal
118  rev bras hematol hemoter. 2 0 1 6;3  8(2):113–120
A B C
E
1q P53 13q
14;164;14
D
Figure 7 – Abnormalities found in ﬁve analyzed samples using the iFISH technique for multiple myeloma. (A) 1q
ampliﬁcation (several red signals); (B) trisomy 17 (3 red and 3 green signals); (C) deletion/monosomy 13q (only one red and
one green signal in one nucleus); (D) 4 red and 4 green signals, suggesting extra copies of chromosomes 4 and 14; (E)
t(14:16): 1 red, 1 green and 2 fusion signals.
Figure 8 – Abnormal metaphase (Sample 11) showing
several abnormalities
(44,X,-Y,add(1)(p34),add(5)(q11.2),del(6)(q23),-7,
t(8;11)(q24;q13),-12,add(13)(p11.2),-14,-16,-18,
+der(19)t(1;19)(q23;p13)x2,add(20)(p13),+2mar[2]/46,XY[18]).
described for targeting the PCs for iFISH analysis. One is per-
formed in unpuriﬁed specimens: the analysis is carried out
using only large mononuclear cells. This method results in
low sensitivity, and involves a long time to train analysts to
recognize the PCs, a prolonged analysis time, a certain degree
of subjectivity and lack of reproducibility.5 The second is the
CIg-FISH technique. This analysis is performed on monotypic
PCs recognized by immunoﬂuorescence-labeled light chain
antibodies.15 This technique, which also requires a long time
for training and does not have good reproducibility, was used
in two Brazilian studies.18,19 The third approach is by selecting
cells either by ﬂow cytometry or immunomagnetic bead-based
PC sorting.4
The current study followed the third approach using the
magnetic cell sorting (MACS) technique giving the impressionthat this method is possible as a routine laboratory test if some
precautions are taken. The magnetic cell sorting must be per-
formed within a few hours. Hartmann et al.5 reported a time
dependence for PC enrichment: the percentage of PCs in the
enriched population decreased signiﬁcantly with the age of
the specimen. This phenomenon is due to the rapid loss of
the CD138 marker on PCs after the cells are taken out of the
bone marrow20; slides are stable and can be stored for a longer
time before the iFISH procedure.
The panel probes herein selected were based on the EMN
consensus. 1q ampliﬁcation, t(4;14), t(14;16) and 17p13 dele-
tion are associated with bad prognoses,4,8,12,21 and the 13q
deletion is still controversial.18 In particular, t(4;14)(p16;q32)
at diagnosis has been shown as a bad prognostic marker,18
even in smoldering MM22,23 and in patients with symptomatic
MM treated with conventional chemotherapy, which may be
ameliorated with bortezomib-based combinations.2
Another important issue is the cut-off levels for FISH
probes. Some authors use statistical analysis (B-inv func-
tion, average and standard deviation) of normal control cases
to determine the cut-off levels. However, to select PCs from
normal bone marrow is very difﬁcult. This study used the con-
sensus cut-off levels deﬁned by the iFISH myeloma workshop:
10% for fusion or breakapart probes and 20% for numeri-
cal abnormalities.4 Nevertheless, in general, bad prognosis is
associated with a higher positivity such as 30% for del(13q)
and 50% for del(17q).
Although the ENM guidelines suggest that a single experi-
enced analyst is considered enough in specialist laboratories,
this study was performed by two technicians (50 cells each). A
good reproducibility was obtained, but in some doubtful cases,
an extra analysis by a third analyst was necessary.
Although only six cases were used in this validation, a high
rate of abnormalities (83.3%) was seen including two cases
of t(4;14), which are markers of a bad prognosis; these cases
would not have been identiﬁed if only conventional karyotyp-
ing was performed as both had normal karyotype results. This
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s higher than our historical detection rate of 34% abnormali-
ies from 2007 to 2014, when samples were sent to a reference
aboratory that performed FISH analysis for MM without PC
election (data not shown, personal communication).
Selection of PCs by MACS  can also be an important tool
or studying the genetic proﬁle of MM with novel methods
uch as microarray-based comparative genomic hybridization
array-CGH), multiplex ligation dependent probe ampliﬁca-
ion (MLPA) and massively parallel sequencing, although the
linical relevance of these methods still needs to be better
stablished.24–26
onclusion
n summary, the iFISH technique using PC sorting with MACS
s effective, has a good turnaround time and good reproducibil-
ty. The test was validated and established in the laboratory
outine. In addition, this kind of cell sorting provides a pure
C population that suitable for other molecular and genomic
tudies.
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